Gonadorelin dosage protocol

What Gonadorelin (GnRH) Is

Gonadorelin, also known as gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH), is a decapeptide (a peptide made of ten amino acids) synthesized and released by the hypothalamus (PMID 1835275, PMID 15544487). It is a neurohormone (PMID 12045004). Analogs of GnRH are synthetic compounds derived from this natural decapeptide (PMID 12045004, PMID 15544487).

How It Is Thought to Work

GnRH regulates the production and release of two pituitary gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by acting on GnRH receptors in the anterior pituitary gland (adenohypophysis) (PMID 1835275, PMID 2675278, PMID 15544487). These gonadotropins, in turn, regulate gonadal steroid production, spermatogenesis, and follicular development in the reproductive organs (PMID 15544487). While traditionally considered the sole regulator of both FSH and LH, a 'dual GnRH model' is proposed where another hormone, cholecystokinin, acts as an FSH-releasing hormone (FSH-RH) in some vertebrates, directly affecting FSH cells and increasing FSH expression and release (animal study, medaka fish; PMID 38937445).

GnRH analogs can suppress the secretion of natural pituitary gonadotropins, leading to a state of 'medical gonadectomy' by reducing sex steroid hormones (PMID 1835275, PMID 12045004). GnRH receptor antagonists block the action of GnRH at the pituitary level (PMID 15544487). The pattern of GnRH administration is crucial; continuous administration can cause flushing, while pulsatile administration does not, suggesting that interference with the natural pulsatile pattern of GnRH causes this side effect (human study; PMID 7713285).

What Laboratory and Animal Studies Report

In medaka fish (an animal model), cholecystokinin (FSH-RH) neurons in the hypothalamus directly influence FSH cells via the Cck2rb receptor, leading to increased FSH expression and release. Knockout of this pathway in medaka minimizes FSH expression and causes a failure of folliculogenesis (animal study, medaka fish; PMID 38937445). GnRH has been observed to inhibit the growth of hormone-dependent human and canine mammary tumors (human and animal cells; PMID 12045004). Immunization against reproductive hormones like LHRH/GnRH can lead to immunoinfertility in animals by blocking receptor sites with antibodies (animal study, cattle; PMID 37869494).

Human Evidence So Far

Parenterally administered GnRH was initially used in humans to diagnose the reserve capacity of LH and FSH in the pituitary gland (PMID 1835275). It was also used therapeutically for hypothalamic hypogonadal and infertility conditions in both men and women (human studies; PMID 1835275). More potent, longer-acting GnRH analogs, administered parenterally or intranasally, have been used in the management of prostate and breast carcinoma, endometriosis, uterine leiomyomata (fibroids), precocious puberty (early puberty), and non-cancerous ovarian hyperandrogenic syndromes (human studies; PMID 1835275).

GnRH agonists are as effective as danazol in treating pelvic pain associated with endometriosis, though they have different side effects due to hypoestrogenism (e.g., hot flushes, osteoporosis) compared to danazol's androgenic side effects (e.g., weight gain, hirsutism) (human studies; PMID 2190793). The common side effect of flushing is linked to interference with the pulsatile pattern of GnRH and dysregulation of the GnRH releasing clock in the hypothalamus (human study; PMID 7713285).

Open Questions and Limitations

While peptidic GnRH agonists and antagonists are clinically exploited, their poor oral bioavailability often limits them to parenteral (non-oral) administration (PMID 15544487). Research is ongoing to develop non-peptidic GnRH receptor antagonists that could offer orally active therapeutic options (PMID 15544487). The ideal drug regimen for endometriosis treatment, balancing efficacy with side effects, is still under development (PMID 2190793).

Key Terms Explained

**Decapeptide:** A peptide composed of ten amino acids (PMID 15544487).

**Hypothalamus:** A region of the brain that produces GnRH (PMID 1835275).

**Anterior Pituitary (Adenohypophysis):** A gland at the base of the brain that responds to GnRH by releasing LH and FSH (PMID 1835275, PMID 2675278).

**Gonadotropins (LH, FSH):** Hormones released by the pituitary that regulate the function of the gonads (testes and ovaries) (PMID 1835275, PMID 15544487).

**Medical Gonadectomy:** A pharmaceutical suppression of gonadal function, similar to surgical removal of the gonads (PMID 1835275, PMID 12045004).

**Parenteral Administration:** Administration of a substance by a route other than the mouth, such as injection (PMID 1835275, PMID 15544487).

**Oral Bioavailability:** The proportion of a drug that enters the circulation when introduced orally and is thus able to have an active effect (PMID 15544487).